Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft—no benefit of combination therapy

BACKGROUND: We initiated this preclinical study in order to analyze the impact of sorafenib single treatment versus combination treatment in human colorectal cancer. METHODS: The effect of increasing sorafenib doses on proliferation, apoptosis, migration, and activation of signal cascades was analyz...

Descripción completa

Detalles Bibliográficos
Autores principales: Wehler, Thomas C., Hamdi, Swaantje, Maderer, Annett, Graf, Claudine, Gockel, Ines, Schmidtmann, Irene, Hainz, Michael, Berger, Martin R., Theobald, Matthias, Galle, Peter R., Moehler, Markus, Schimanski, Carl C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587684/
https://www.ncbi.nlm.nih.gov/pubmed/22983756
http://dx.doi.org/10.1007/s00384-012-1551-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587684/
https://www.ncbi.nlm.nih.gov/pubmed/22983756
http://dx.doi.org/10.1007/s00384-012-1551-2

Ejemplares similares